BowTiedBiotech
BowTiedBiotech Podcast
The "Pill Penalty" and the Inflation Reduction Act | Ep. 713
0:00
-8:52

The "Pill Penalty" and the Inflation Reduction Act | Ep. 713

IRA Side Effects: Biotech’s Small Molecule Squeeze

Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.

We are now publishing 7x per week according to the following cadence:

  • Mondays: Stocks

  • Tuesdays: Biotech

  • Wednesdays: Podcast

  • Thursdays: Markets

  • Fridays: News

  • Saturdays: Podcast

  • Sundays: Strategy

We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.

SUBSCRIBE TO PODCAST HERE:

Please help spread the work by subscribing and hitting the share button if you are enjoying content!

Image

Welcome back to BowtiedBiotech, where science meets strategy. In this episode, we dive deep into the Inflation Reduction Act and the ripple effects it's creating across the biotech landscape. From the controversial "pill penalty" to the orphan drug exemption that isn't quite what it seems, we unpack how this landmark policy is reshaping incentives, pipelines, and patient access. Whether you're a founder, investor, or policy wonk, this one’s for you, because what looks like cost control on the surface might just be choking the next wave of medical innovation.

📣🎙️ TODAY’S PODCAST:

[ 0:00 ] Introduction

[ 0:33 ] Inflation Reduction Act

[ 1:11 ] Pill penalty

[ 2:46 ] Orphan drugs

[ 4:42 ] Unintended consequences

[ 6:00 ] Targeted policy reform

[ 7:22 ] Framing the issue

[ 7:52 ] Balancing affordability & innovation

Thanks for reading BowTiedBiotech! Please help us grow our audience - sharing is caring!

Share

CONCLUSION

We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!

As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com

ABOUT BOWTIEDBIOTECH

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

DISCLAIMER

None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.  

TOP BOWTIEDBIOTECH NEWSLETTERS

Discussion about this episode

User's avatar